FIELD: biotechnology.
SUBSTANCE: disclosed is a stable composition suitable for use in treating a tumour or cancer associated with PD-1, containing a recombinant monoclonal antibody against PD-1 in amount of 10–25 mg/ml; buffer in concentration of 20–40 mM; an osmolarity regulator at concentration of 80–160 mM; stabilizer in concentration of 20–205 mM; surfactant in amount of 0.02–0.04 wt.%, wherein the pH of solution is 5.5–6.5, and also disclosed is its use for preparing a drug for treating a tumour or cancer associated with PD-1.
EFFECT: said composition can increase stability of said antibody and prolongs the shelf life of said antibody in aqueous compositions.
16 cl, 8 dwg, 11 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTIBODY OR ITS ANTIGEN-BINDING FRAGMENT (FAB) AGAINST FIRST AND/OR SECOND TYPE SHIGA LIKE TOXINS (EMBODIMENTS), COMPOSITION FOR TREATING ENTEROHAEMORRHAGIC ESCHERICHIA COLI TOXIC CONDITIONS, CONTAINING SAID ANTIBODIES AND/OR FAB | 2019 |
|
RU2732155C1 |
| NEUTRALIZATION OF LYMPHOCYTE INHIBITORY PATHWAYS | 2015 |
|
RU2734771C2 |
| Fab FRAGMENT OF HUMANIZED ANTIBODY AGAINST VEGF AND ITS USE | 2020 |
|
RU2802960C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROTEIN 1 OF PROGRAMMED CELL DEATH (PD-1) | 2017 |
|
RU2768404C2 |
| HUMANIZED ANTI-IL17A ANTIBODY AND ITS APPLICATION | 2020 |
|
RU2804963C2 |
| HUMANIZED ANTIBODY AGAINST PD-1 AND ITS USE | 2019 |
|
RU2803460C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| INHIBITORY PATHWAY NEUTRALIZATION IN LYMPHOCYTES | 2017 |
|
RU2769569C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
| PD1 ANTIBODIES AND THEIR APPLICATION METHODS | 2016 |
|
RU2746409C1 |
